EMD Millipore Introduces New Excipient for Enhanced Drug Solubility and Bioavailability
22 Oct 2013EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, today introduced Parteck® SLC, a new excipient with a unique surface structure that delivers significantly increased loadability for active pharmaceutical ingredients (API). Featuring a unique pore structure, Parteck® SLC for drug delivery enables loading of oral dosage forms with amorphously distributed API to the highest levels, dramatically increasing API solubility.
"Many promising drug candidates fail during development due to poor bioavailability and represent a significant loss of time and resources invested in drug development," noted Matthias Bucerius, Ph.D., Head of Pharmaceutical Raw Materials. "With the addition of Parteck® SLC to our extensive portfolio of excipients, drug developers now have a new option to help increase solubility and bioavailability and advance drug development. With Parteck® SLC, molecules can also be reformulated, potentially extending the life cycle of the drug."
Parteck® SLC's mesopores (2-7 nm) create a surface area of up to 1000 m2/g for depositing an API in its amorphous form needed for supersaturation. The internal surface area of Parteck® SLC is also easily accessible and the API is always kept stable. Feasibility studies have proven the superior performance on dissolution of Parteck® SLC both in vitro and in vivo.
A user-friendly particle size (5-25 μm) and bulk density (0.32 g/ml) allow easy loading, tableting, or capsule creation. In conjunction with Parteck® ODT, a directly compressible excipient, Parteck® SLC helps to produce stable and fast acting tablets. The loaded granulate retains its performance during dissolution in solid dosage forms.
As an EMPROVE® product, Parteck® SLC comes with ready-to-use documentation in CTD-format, saving time and money in the registration of the final drug. Feasibility studies concerning loading and in vitro dissolution are also available
Related Products
Request Quote for All Products
Parteck® SLC Excipients
MerckCreated specifically for solid dosage forms, Parteck® excipients are distinguished by outstanding functionalities and a unique particle structure. All Parteck® products are developed under our Functional Particle Engineering concept comprising advanced EMD Millipore technologies for quite extraordinary functionally relevant particle properties. These properties of Parteck® excipients offer decisive advantages to the formulator compared to other tabletting excipients on the market – especially when it comes to sensitive formulations.With Parteck®, formulators benefit from excellent tabletting behavior: Thanks to the high compressibility of Parteck® excipients, you can produce harder tablets using lower compression forces – thus reducing strain on your tabletting equipment. In addition, your tablets will take effect much faster, because our Parteck® products improve their disintegration time and accelerate API release. The greater surface area of Parteck® particles improves integration and content uniformity. Moreover, we have optimized their flow behavior – for easier blending and a stable, high-throughput process.By making your formulations easier, Parteck® from EMD Millipore saves valuable development time and resources. As a matter of course, every single batch of Parteck® excipients features the uncompromising quality you have come to expect from EMD Millipore. What’s more, most Parteck® excipients are EMPROVE® products, thus offering full documentation to speed up approvals.Parteck® SLC Excipients Features & Benefits: Outstanding tabletting behavior. Excellent compressibility for harder tablets. Fast disintegration for rapid onset of action. Optimized flow. EMPROVE® documentation.